Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726229 · ClinicalTrials.gov registry record
Cholate Clearance in Fontans
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 50
- Enrollment target
NCT03726229: Completed study, sponsored by University of Pennsylvania.
NCT03726229 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03726229 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
HepQuant is an assay to measure liver function in other forms of liver disease such as hepatitis C. It measures the ability of the liver to process an naturally occurring substance called cholate and has been shown to predict clinical outcomes in some patient populations. The Fontan survivor is a patient who has undergone surgery or a series of surgeries that result in a functional single ventricle. The liver is particularly vulnerable to disease including congestion, fibrosis, and even cirrhosis. Currently liver function in the Fontan is not well-characterized and the HepQuant assay could help answer this question.
Interventions
- DEVICE Cholate assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-05-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726229
The ClinicalTrials.gov registry entry for NCT03726229 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cholate assay is the first listed.
NCT03726229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03726229 about?
NCT03726229 is a clinical study titled "Cholate Clearance in Fontans". HepQuant is an assay to measure liver function in other forms of liver disease such as hepatitis C. It measures the ability of the liver to process an naturally occurring substance called cholate and has been shown to predict clinical outcomes in some patient populations. The Fontan survivor is a p...
What is the current status of trial NCT03726229?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2019-05-01. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT03726229?
The interventions under investigation include: Cholate assay (DEVICE).
Who is sponsoring clinical trial NCT03726229?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.